U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106372) titled 'A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis' on Aug. 05.
Brief Summary: This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
BIOLOGICAL: Stapokibatrt
Stapokibatrt Subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Keymed Biosciences Co.Ltd
Disclaimer: Curated by HT Syndication....